Management of metastatic prostate cancer continues to evolve. The widespread use of the prostate-specific antigen (PSA) assay has led to earlier diagnosis and earlier detection of recurrent disease. Debates continue regarding the proper use and timing of endocrine therapy with orchiectomy, estrogen agonists, luteinizing hormone–releasing hormone (LHRH) analogs, LHRH antagonists, and androgen antagonists.
Methods
The authors reviewed the significant published materials of the last 20 years that have shaped hormonal management of metastatic and progressive prostate cancer. Major areas of controversy were also identified.
Results
The present approach to hormonal management is summarized. Five potential pathways to the development of androgen-independent prostate cancer are described. Controversial topics of hormonal management, including immediate vs delayed hormonal therapy, monotherapy vs maximal androgen blockade (MAB), and intermittent hormonal therapy, are discussed.
Conclusions
Orchiectomy, estrogen agonists, and LHRH analogs have therapeutic equivalence. Patients who have a rising PSA after definitive treatment for prostate cancer and high risk of recurrent disease may warrant early androgen deprivation. MAB does not appear to be significantly better than single-agent LHRH analog therapy. Intermittent therapy may delay emergence of androgen independence and maintain or improve quality of life.
References
1.
FeldmanB.J., FeldmanD.. The development of androgen-independent prostate cancer.Nature Rev Cancer.2001; 1: 34–45.
2.
RuijterE., van de KaaC., MillerG.. Molecular genetics and epidemiology of prostate carcinoma.Endocr Rev.1999; 20: 22–45.
3.
TilleyW.D., BuchananG., HickeyT.E.. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.Clin Cancer Res.1996; 2: 277–285.
4.
TaplinM.E., BubleyG.J., ShusterT.D.. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.N Engl J Med.1995; 332: 1393–1398.
5.
TaplinM.E., BubleyG.J., KoY.J.. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer Res.1999; 59: 2511–2515.
6.
CraftN., ChhorC., TranC.. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.Cancer Res.1999; 59: 5030–5036.
7.
KoivistoP., KononenJ., PalmbergC.. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.Cancer Res.1997; 57: 314–319.
8.
VisakorpiT., HyytinenE., KoivistoP.. In vivo amplification of the androgen receptor gene and progression of human prostate cancer.Nat Genet.1995; 9: 401–406.
9.
GregoryC.W., JohnsonRTJr, MohlerJ.L.. Androgen receptor stabilization in recurrent prostate cancer is associated with hyper-sensitivity to low androgen.Cancer Res.2001; 61: 2892–2898.
10.
LabrieF., DupontA., BelangerA.. Treatment of prostate cancer with gonadotropin-releasing hormone agonists.Endocr Rev.1986; 7: 67–74.
11.
BuchananG., GreenbergN.M., ScherH.I.. Collocation of androgen receptor gene mutations in prostate cancer.Clin Cancer Res.2001; 7: 1273–1281.
12.
VeldscholteJ., BerrevoetsC.A., Ris-StalpersC.. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.J Steroid Biochem Mol Biol.1992; 41: 665–669.
13.
SmallE.J., SrinivasS.. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.Cancer.1995; 76: 1428–1434.
14.
McGuireW.L., ChamnessG.C., FuquaS.A.. Estrogen receptor variants in clinical breast cancer.Mol Endocrinol.1991; 5: 1571–1577.
15.
BorgA., BaldetorpB., FernoM.. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.Cancer Lett.1994; 81: 137–144.
16.
PietrasR.J., ArboledaJ., ReeseD.M.. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.Oncogene.1995; 10: 2435–2446.
17.
CraftN., ShostakY., CareyM.. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.Nat Med.1999; 5: 280–285.
18.
YehS., LinH.K., KangH.Y.. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.Proc Natl Acad Sci U S A.1999; 96: 5458–5463.
19.
McDonnellT.J., TroncosoP., BrisbayS.M.. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.Cancer Res.1992; 52: 6940–6944.
20.
ColombelM., SymmansF., GilS.. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.Am J Pathol.1993; 143: 390–400.
21.
IsaacsJ.T.. The biology of hormone refractory prostate cancer: why does it develop?Urol Clin North Am.1999; 26: 263–273.
22.
DenmeadeS.R., LinX.S., IsaacsJ.T.. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.Prostate.1996; 28: 251–265.
23.
CoppageWSJr, CoonerA.E.. Testosterone in human plasma.N Engl J Med.1965; 273: 902–907.
24.
YoungHHII, KentJ.R.. Plasma testosterone levels in patients with prostatic carcinoma before and after treatment.J Urol.1968; 99: 788–792.
25.
OefeleinM.G., FengA., ScolieriM.J.. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.Urology.2000; 56: 1021–1024.
26.
SandowJ., von RechenbergW., EngelbartK.. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.Am J Clin Oncol.1988; 11(suppl 1): S6–10.
27.
GellerJ., AlbertJ., VikA.. Advantages of total androgen blockade in the treatment of advanced prostate cancer.Semin Oncol.1988; 15(2 suppl 1): 53–61.
28.
GellerJ.. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.Semin Oncol.1985; 12(1 suppl 1): 28–35.
29.
Treatment and survival of patients with cancer of the prostate.The Veterans Administration Co-operative Urological Research Group.Surg Gynecol Obstet.1967; 124: 1011–1017.
30.
JordanWPJr, BlackardC.E., ByarD.P.. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.South Med J.1977; 70: 1411–1413.
31.
ByarD.P., CorleD.K.. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.NCI Monogr.1988; 165–170.
32.
SolowayM.S., ChodakG., VogelzangN.J.. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.Urology.1991; 37: 46–51.
33.
Leuprolide versus diethylstilbestrol for metastatic prostate cancer: the Leuprolide Study Group.N Engl J Med.1984; 311: 1281–1286.
34.
PantelidesM.L., BowmanS.P., GeorgeN.J.. Levels of prostate specific antigen that predict skeletal spread in prostate cancer.Br J Urol.1992; 70: 299–303.
35.
StegeR.. Potential side effects of endocrine treatment of long duration in prostate cancer.Prostate Suppl.2000; 10: 38–42.
36.
MoyadM.A.. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women.Urology.2002; 59(4 suppl 1): 20–33.
37.
RobinsonM.R.. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.Prog Clin Biol Res.1988; 260: 101–110.
38.
RaynaudJ.P., CoussediereD., MoguilewskyM.. Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment [French].Bull Cancer.1986; 73: 36–46.
39.
BubleyG.J.. Is the flare phenomenon clinically significant?Urology.2001; 58(2 suppl 1): 5–9.
40.
LabrieF., DupontA., BelangerA.. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.J Urol.1987; 138: 804–806.
41.
LoweF.C., SomersW.J.. The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer.J Urol.1987; 137: 1000–1002.
42.
SeidenfeldJ., SamsonD.J., HasselbladV.. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.Ann Intern Med.2000; 132: 566–577.
43.
SeidenfeldJ., SamsonD.J., AronsonN.. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.Evid Rep Technol Assess (Summ).1999: i–x, 1-246, I1-36, passim.
44.
BoccardoF., RubagottiA., BarichelloM.. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.J Clin Oncol.1999; 17: 2027–2038.
45.
CookT., SheridanW.P.. Development of GnRH antagonists for prostate cancer: new approaches to treatment.Oncologist.2000; 5: 162–168.
TrachtenbergJ., GittlemanM., SteidleC.. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.J Urol.2002; 167: 1670–1674.
48.
TomeraK., GleasonD., GittelmanM.. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.J Urol.2001; 165: 1585–1589.
49.
McLeodD., ZinnerN., TomeraK.. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.Urology.2001; 58: 756–761.
50.
ByarD.P.. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.Cancer.1973; 32: 1126–1130.
51.
WalshP.C., DeWeeseT.L., EisenbergerM.A.. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment.J Urol.2001; 166: 508–516.
52.
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial.The Medical Research Council Prostate Cancer Working Party Investigators Group.Br J Urol.1997; 79: 235–246.
53.
BollaM., GonzalezD., WardeP.. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.N Engl J Med.1997; 337: 295–300.
54.
PilepichM.V., CaplanR., ByhardtR.W.. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.J Clin Oncol.1997; 15: 1013–1021.
55.
GranforsT., ModigH., DamberJ.E.. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study.J Urol.1998; 159: 2030–2034.
56.
MessingE.M., ManolaJ., SarosdyM.. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.N Engl J Med.1999; 341: 1781–1788.
57.
NairB., WiltT., MacDonaldR.. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.Cochrane Database Syst Rev.2002: CD003506.
58.
PoundC.R., PartinA.W., EisenbergerM.A.. Natural history of progression after PSA elevation following radical prostatectomy.JAMA.1999; 281: 1591–1597.
59.
CrawfordE.D., EisenbergerM.A., McLeodD.G.. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.N Engl J Med.1989; 321: 419–424.
60.
DenisL.J., Carnelro de MouraJ.L., BonoA.. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.Urology.1993; 42: 119–130.
61.
JanknegtR.A., AbbouC.C., BartolettiR.. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.J Urol.1993; 149: 77–83.
62.
EisenbergerM.A., BlumensteinB.A., CrawfordE.D.. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.N Engl J Med.1998; 339: 1036–1042.
63.
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.Prostate Cancer Trialists’ Collaborative Group.Lancet.2000; 355: 1491–1498.
64.
SchmittB., WiltT.J., SchellhammerP.F.. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.Urology.2001; 57: 727–732.
65.
MoinpourC.M., SavageM.J., TroxelA.. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.J Natl Cancer Inst.1998; 90: 1537–1544.
66.
FletcherJ.M., LobleyG.E., ConnellA.. Effects on growth and body composition of androgen deprivation by castration or autoimmunization to LH-releasing hormone in the male rat under conditions of controlled food intake.J Endocrinol.1986; 110: 97–102.
67.
SlusserW.N., WadeG.N.. Testicular effects on food intake, body weight, and body composition in male hamsters.Physiol Behav.1981; 27: 637–640.
68.
RothwellN.J., StockM.J.. Increased body-weight gain and body protein in castrated and adrenalectomized rats treated with clenbuterol.Br J Nutr.1988; 60: 355–360.
69.
DanielsenC.C., MosekildeL., AndreassenT.T.. Long-term effect of orchidectomy on cortical bone from rat femur: bone mass and mechanical properties.Calcif Tissue Int.1992; 50: 169–174.
70.
HodgkinsonA.. Effects of calcium deprivation and orchidectomy on bone composition in the rat.Horm Metab Res.1979; 11: 516–519.
71.
WinkC.S., FeltsW.J.. Effects of castration on the bone structure of male rats: a model of osteoporosis.Calcif Tissue Int.1980; 32: 77–82.
72.
VerhasM., SchoutensA., L'Hermite-BaleriauxM.. The effect of orchidectomy on bone metabolism in aging rats.Calcif Tissue Int.1986; 39: 74–77.
73.
DaniellH.W.. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.Urology.2001; 58(2 suppl 1): 101–107.
74.
KiratliB.J., SrinivasS., PerkashI.. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.Urology.2001; 57: 127–132.
75.
TayekJ.A., HeberD., ByerleyL.O.. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer.Metabolism.1990; 39: 1314–1319.
76.
NobleR.L.. Hormonal control of growth and progression in tumors of Nb rats and a theory of action.Cancer Res.1977; 37: 82–94.
77.
BruchovskyN., RennieP.S., ColdmanA.J.. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.Cancer Res.1990; 50: 2275–2282.
78.
SandfordN.L., SearleJ.W., KerrJ.F.. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation.Pathology.1984; 16: 406–410.
GoldenbergS.L., BruchovskyN., GleaveM.E.. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.Urology.1995; 45: 839–845.
81.
HorwichA., HuddartR.A., GaddJ.. A pilot study of intermittent androgen deprivation in advanced prostate cancer.Br J Urol.1998; 81: 96–99.
82.
CrookJ.M., SzumacherE., MaloneS.. Intermittent androgen suppression in the management of prostate cancer.Urology.1999; 53: 530–534.
83.
HiganoC.S., EllisW., RussellK.. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.Urology.1996; 48: 800–804.
84.
GrossfeldG.D., ChaudharyU.B., ReeseD.M.. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.Urology.2001; 58: 240–245.
